High dose naloxone does not improve cerebral or myocardial blood flow during cardiopulmonary resuscitation in pigs

Resuscitation

Volumn 34, Issue 3, 1997, Pages 255-261

  Gervais, Hendrik W ^a   Eberle, Balthasar ^a   Hennes, Hans Juergen ^a   Grimm, Werner ^a   Kilian, Andrea ^a   Konietzke, Dieter ^a   Massing, Christof ^a   Dick, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cardiopulmonary resuscitation; Epinephrine; Naloxone; Organ blood flow; Pigs; Radiolabeled microspheres

Indexed keywords

ADRENALIN; MICROSPHERE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTERIAL GAS; ARTICLE; BRAIN BLOOD FLOW; CLINICAL TRIAL; COMPRESSION; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEART ARREST; HEART HEMODYNAMICS; HEART MUSCLE BLOOD FLOW; HEART RIGHT ATRIUM PRESSURE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SWINE; TIME;

ACID-BASE EQUILIBRIUM; ANIMALS; CARDIOPULMONARY RESUSCITATION; CEREBROVASCULAR CIRCULATION; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; NALOXONE; NARCOTIC ANTAGONISTS; SWINE;

EID: 0030969865     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(96)01066-0     Document Type: Article

References (69)

1. Guillemin R, Vargo T, Rossier J, Minick S, Ling N, Rivier C, Vale W, Bloom F. β-Endorphin and adrenocorticotropin are secreted concomittantly by the pituitary gland. Science 1977; 197: 1367-1369.
2. Rees M, Bowen JC, Payne JG, MacPhee AA. Plasma β-endorphin immuno-reactivity in dogs during anesthesia, surgery, Escherichia coli sepsis, and naloxone therapy. Surgery 1983; 93: 386-390.
3. Bertolini A. The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. Resuscitation 1995; 30: 29-42.
4. Barsan WG, Hedges JR, Syverud SA. Hemodynamic effects of naloxone in anaphylactic shock. Resuscitation 1986; 13: 223-231.
5. Bernton EW, Long JB, Holaday JW. Opioids and neuropeptides: mechanisms in circulatory shock. Fed Proc 1985; 44: 290-299.
6. Faden AI. Opiate antagonists and thyrotropin-releasing hormone. I. Potential role in the treatment of shock. JAMA 1984; 252: 1177-1180.
7. Baskin DS, Hosobuchi Y. Naloxone reversal of ischemic neurological deficits in man. Lancet 1982; II: 272-275.
8. Iselin HU, Weiss P. Naloxone reversal of ischemic neurological deficits. Lancet 1981; II: 642-643.
9. Adams Jr. HP, Olinger CP, Barsan WG, Butler MJ, Graff-Radford NR, Brott TG, Biller J, Damasio H, Tomsick T, Goldberg M, Spilker JA, Berlinger E, Dambrosia J, Biros M, Hollern R. A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia. Stroke 1986; 17: 404-409.
10. Czlonkowska A, Cyrta B. Effect of naloxone on acute stroke. Pharmacopsychiatry 1988; 21: 98-100.
11. Krechel SW, Orr RM, Couper NB, Gupta N, Eggers GWN Jr. Naloxone: report of a beneficial side effect. J Neurosurg Anesth 1989; 1: 346-351.
12. Faden AI, Hallenbeck JM, Brown CQ. Treatment of experimental stroke: comparison of naloxone and thyrotropin releasing hormone. Neurology 1982; 32: 1083-1087.
13. Hariri RJ, Supra EL, Roberts JP, Lavyne MH. Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. J Neurosurg 1986; 64: 780-786.
14. Holtz A, Nyström B, Gerdin B. Blocking weight-induced spinal cord injury in rats: effects of TRH or naloxone on motor function recovery and spinal cord blood flow. Acta Neurol Scand 1989; 80: 215-220.
15. Wexler BC. Naloxone ameliorates the pathophysiologic changes which lead to and attend an acute stroke in stroke-prone/SHR. Stroke 1984; 15: 630-634.
16. Cutler VR, Bredesen DE, Edwards R, Simon RB. Failure of naloxone to reverse vascular neurologic deficits. Neurology 1983; 33: 1517-1518.
17. Fallis RJ, Fisher M, Lobo RA. A double-blind trial of naloxone in the treatment of acute stroke. Stroke 1984; 15: 627-629.
18. Holaday JW, D'Amato RJ. Naloxone or TRH fails to improve neurologic deficits in gerbil models of 'stroke'. Life Sci 1982; 31: 385-392.
19. Kastin AJ, Nissen C, Olson RD. Failure of MIF-1 or naloxone to reverse ischemic-induced neurologic deficits in gerbils. Pharmacol Biochem Behav 1982; 17: 1083-1085.
20. Hubbard JL, Sundt TM. Failure of naloxone to affect focal incomplete cerebral ischemia and collateral blood flow in cats. J Neurosurg 1983; 59: 237-244.
21. Sakaguchi A, Dohrmann GJ, Mojtahedi S. Experimental vasospasm: Experiences with a canine model and failure of naloxone therapy. Surg Neurol 1984; 22: 527-531.
22. Koskinen LOD. Effects of raised intracranial pressure on regional cerebral blood flow: a comparison of effects of naloxone and TRH on the microcirculation in partial cerebral ischaemia. Br J Pharm 1985; 85:489-497.
23. Haghighi SS, Chehrazi B. Effect of naloxone in experimental spinal cord injury. Neurosurgery 1987; 20: 385-388.
24. Obana WG, Pitts LH, Nishimura MC. Effect of opiate antagonists on middle cerebral artery occlusion infarct in the rat. J Neurosurg 1988; 69: 98-103.
25. Symoens J, van Gestel LJ. Klinische Prüfung des Kombination-sanaesthetikums Azaperon-Metomidat beim Schwein. Tierärztl Umschau 1973; 28: 562-566.
26. Heyman MA, Payne BD, Hoffman JR, Rudolph AM. Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis 1977; 20: 55-79.
27. Koehler RC, Chandra N, Guerci AD, Tsitlik J, Traystman RJ, Rogers MC, Weisfeldt ML. Augmentation of cerebral perfusion by simultaneous chest compression and lung inflation with abdominal binding after cardiac arrest in dogs. Circulation 1983; 67: 266-275.
28. Marcus ML, Heistad DD, Ehrhardt JC, Abboud FM. Total and regional cerebral blood flow measurement with 7-10-, 15-, 25-, and 50-μm microspheres. J Appl Physiol 1976; 40: 501-507.
29. Chen RYZ, Fan FC, Schuessler GB, Usami S, Chien S. Effects of sphere size and injection site on regional cerebral blood flow measurements. Stroke 1983; 14: 769-776.
30. Buckberg GD, Luck JC, Payne DB, Hoffman JIE, Archie JP, Fixler DE. Some sources of error in measuring regional blood flow with radioactive microspheres. J Appl Physiol 1971; 31: 598-604.
31. Dole WP, Jackson DL, Rosenblatt JI, Thompson WL. Relative error and variability in blood flow measurements with radiolabeled microspheres. Am J Physiol 1982; 243: H371-H378.
32. Modin BE, Ganes E, Reynolds DG, Gurll NJ. Naloxone requires circulating catecholamines for efficacy in primate hemorrhagic shock (Abstr.). Fed Proc 1985; 44: 1574.
33. Allgood SC, Gurll NJ, Reynolds DG. Naloxone requires circulating catecholamines to attenuate the cardiovascular suppression of endotoxic shock. J Surg Res 1988; 44: 73-81.
34. Foley PJ, Tacker WA, Voorhees WD, Ralston SH, Elchisak MA. Effects of naloxone on the adrenomedullary response during and after cardiopulmonary resuscitation in dogs. Am J Emerg Med 1987; 5: 357-361.
35. Rothstein RJ, Niemann JT, Rennie III CJ, Suddath WO. Use of naloxone during cardiac arrest and CPR: potential adjunct for postcountershock electrical-mechanical dissociation. Ann Emerg Med 1985; 14: 198-203.
36. Curtis MT, Lefer AM. Protective actions of naloxone in hemorrhagic shock. Am J Physiol 1980; 239: H416-H421.
37. Sagy M, Shavit G, Oron Y, Gitter S, Sarna Y. Naloxone's inotropic properties in relation to opiate and adrenergic receptors (Abstr.). Crit Care Med 1986; 14: 392.
38. Brasch H. Influence of the optical isomers (+) and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations. Br J Pharmacol 1986; 88: 733-740.
39. Downey J. Compression of the coronary arteries by the fibrillating canine heart. Circ Res 1976; 39: 53-57.
40. Livesay JL, Follette DM, Fey KH, Nelson RL, DeLand EC, Barnard RJ, Buckberg GD. Optimizing myocardial supply/demand balance with α-adrenergic drugs during cardiopulmonary resuscitation. J Thorac Cardiovasc Surg 1978; 76: 244-251.
41. Ditchey RV, Lindenfeld JA. Failure of epinephrine to improve the balance between myocardial oxygen supply and demand during closed-chest resuscitation in dogs. Circulation 1988; 78: 382-389.
42. Lindner KH, Ahnefeld FW, Schürmann W, Pfenninger E. Einfluss von Adrenalin und Noradrenalin auf die Sauerstoffversorgung des Myokards während der kardiopulmonalen Reanimation. Anaesthesist 1989; 38: 245-250.
43. Gervais HW, Schleien CL, Koehler RC, Berkowitz ID, Shaffner DH, Traystman RJ. Effect of adrenergic drugs on cerebral blood flow, metabolism, and evoked potentials after delayed cardiopulmonary resuscitation in dogs. Stroke 1991; 22: 1554-1561.
44. Sarne Y, Hochman I, Eshed M, Oppenheimer E. Antiarrhythmic action of naloxone: direct, non-opiate effect on the rat heart. Life Sci 1988; 43: 859-864.
45. Fagbemi O, Lepràn I, Parratt JR, Szekeres L. Naloxone inhibits early arrhythmias resulting from acute coronary ligation. Br J Pharmacol 1982; 76: 504-506.
46. Huang XD, Lee AYS, Wong TM, Zhan CY, Zhao YY. Naloxone inhibits arrhtyhmias induced by coronary artery occlusion and reperfusion in anaesthetized dogs. Br J Pharmacol 1986; 87: 475-477.
47. Bergey JL, Beil ME. Antiarrhythmic evaluation of naloxone against acute coronary occlusion-induced arrhythmias in pigs. Eur J Pharmacol 1983; 90: 427-431.
48. Lechner RB, Gurll NJ, Reynolds DG. Naloxone potentiates the cardiovascular effects of catecholamines in canine hemorrhagic shock. Circ Shock 1985; 16: 347-361.
49. Long JB, Lake CR, Reid AA, Holaday JW. Effects of naloxone and thyrotropin-releasing hormone on plasma catecholamines, corticosterone, and arterial pressure in normal and endotoxemic rats. Circ Shock 1986; 18: 1-10.
50. Bouloux PM, Grossman A, Besser GM. Naloxone provokes catecholamine release in phaeochromocytomas and paragangliomas. Clin Endocrinol 1986; 24: 319-325.
51. Mannelli M, Maggi M, De Feo ML, Cuomo S, Forti G, Moroni F, Giusti G. Naloxone administration releases catecholamines. N Engl J Med 1983; 380: 654-655.
52. Martinez A, Padbury J, Shames L, Evans C, Humme J. Naloxone potentiates epinephrine release during hypoxia in fetal sheep: dose response and cardiovascular effects. Pediatr Res 1988; 23: 343-347.
53. Malcolm DS, Zaloga GP, Willey SC, Amir S, Holaday JW. Naloxone potentiates epinephrine's pressor actions in endotoxemic rats. Circ Shock 1988; 25: 259-265.
54. Dziki AJ, Lynch WH, Ramsey CB, Law WR. β-adrenergic-dependent and -independent actions of naloxone on perfusion during endotoxin shock. Circ Shock 1993; 39: 29-38.
55. Feigl EO. Coronary physiology. Physiol Rev 1983; 63: 1-205.
56. Michael JR, Guerci AD, Koehler RC, Shi AY, Tsitlik J, Chandra N, Niedermeyer E, Rogers MC, Traystman RJ. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69: 822-835.
57. Tintinalli JE, Zwanger M, Koster K. Effect of naloxone on cerebral blood flow postarrest (Abstr.). Ann Emerg Med 1985; 14: 507.
58. Turner DM, Kassell NF, Sasaki T, Comair YG, Beck, DO, Boarini DJ. High dose naloxone produces cerebral vasodilation. Neurosurg 1984; 15: 192-197.
59. Turner DM, Kassell NF, Sasaki T, Comair YG, Beck, DO, Klein SL. Cerebral and systemic vascular effects of naloxone in pentobarbital-anesthetized normal dogs. Neurosurg 1984; 14: 276-282.
60. Turner DM, Kassell NF, Sasaki T, Comair YG, Boarini DJ, Beck DO. Effects of naloxone on cerebral blood flow and metabolism in isoflurane/nitrous oxide-anesthetized dogs. Neurosurg 1984; 14: 688-696.
61. Sasaki T, Kassell NF, Turner DM, Maixner W, Torner JC, Coester HC. Effects of naloxone on canine cerebral vascular smooth muscle. J Cerebr Blood Flow Metabol 1984; 4: 166-172.
62. Phillis JW, DeLong RE, Towner JK. Naloxone enhances cerebral reactive hyperemia in the rat. Neurosurg 1985; 17: 596-599.
63. Sandor P, Cox-van Put J, de Jong W, de Wied D. Continuous measurement of cerebral blood volume in rats with the photoelectric technique: effect of morphine and naloxone. Life Sci 1986; 39: 1657-1665.
64. Miller JD, Bell BA. Cerebral blood flow. Variations with perfusion pressure and metabolism. In: Wood JH, editor. Cerebral blood flow. Physiologic and clinical aspects. McGraw-Hill, New York, St. Louis, San Francisco, 1987; 119-130.
65. Rapoport SI. Effect of concentrated solutions on blood-brain barrier. Am J Physiol 1970; 219: 270-274.
66. Rapoport SI, Hori M, Klatzo I. Testing a hypothesis for osmotic opening of the blood-brain barrier. Am J Physiol 1972; 223: 323-331.
67. Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 1980; 238: R421-R431.
68. Bretschneider H. Osmolalities of commercially supplied drugs often used in anesthesia. Anesth Analg 1987; 66: 361-362.
69. Goetting MG, Paradis NA. Right atrial-jugular venous pressure gradients during CPR in children. Ann Emerg Med 1991; 20: 27-30.